Methyldopa In Treatment Research Articles

Oral Labetalol in Comparison with Methyldopa in Treatment of Gestational Hypertension as a First Line Drug

Background: Defining hypertension in pregnancy, it is taken as systolic blood pressure of 140 or more and diastolic blood pressure of 90mg or more. Presence of proteinurea differentiates chronic hypertension and gestational hypertension from pre eclampsia .Prevalence and incidence of hypertension in pregnancy along with its complications like end-organ damage, preeclampsia, eclampsia, and postpartum eclampsia are increasing. Gestational hypertension and its sequels are major causes of fetal and maternal morbidity and mortality and affect almost 8% of pregnancies. Labetalol and methyldopa were effective in reducing systolic and diastolic BP significantly but labetalol was found to control BP more rapidly and efficiently. Safety profile of both drugs was similar. The rationale of this study is Labetalol is more effective in comparison with Methyldopa in pregnancy induced hypertensive females in terms of control of blood pressure within 48hours of drug intake, in pregnant patients between POG of 28 to 32 weeks. Design: Randomized control trial. Place and Duration of Study: Department of Gynaecology Unit 2 Bahawal Victoria Hospital, Bahawalpur from 1st January 2022 to 31st December 2022. Methodology: One hundred 100 patients having gestational hypertension between periods of gestation from 28to 32 weeks were enrolled. They were divided into 2 groups; group A treated with labetalol and B treated with methyldopa respectively. Results: Statistical no significant difference in systolic and diastolic blood pressure was observed before starting treatment in both groups but a significant fall in diastolic blood pressure was observed in group A after 48 hrs of initiation of treatment i.e., with labetalol (P = 0.007) Conclusion: Both labetalol and methyldopa reduce blood pressure in women with gestational hypertension but labetalol is more effective than methyldopa as proved by our study. Keywords: Gestational hypertension, Diastolic blood pressure, Labetalol, Methyldopa

The Efficacy of Labetalol and Methyldopa in Treatment of Pregnancy Induced Hypertension

Background: Many people still lack access to health care in countries like Bangladesh, despite the country's impressive record of improvement and growth in this area. Pregnancy-related hypertension is the most prevalent medical issue. Objective: In this study our main goal is to compare the efficacy of labetalol and methyldopa in treatment of pregnancy induced hypertension. Method: This study was conducted in the Department of Obstetrics and Gynaecology, Abdul Malek Ukil Medical College, Noakhali over a period of 2 years from September 2019 to September 2021, after taking ethical committee clearance. 180 Pregnancy Induced Hypertensive women after 20 weeks of pregnancy coming to hospital over a period of 2 years on IPD basis from September 2019 to September 2012 were included as sample size. Among 180 patients of PIH, 90 were given Labetalol (group A) and 90 were given Methyldopa (group B). Results: during the study, with labetalol, the mean arterial pressure on admission was 109.48mmHg which reduced to 96.90mmHg on day 7. Reduction in MAP was statistically significant. On comparing the two drugs, MAP on admission were comparable but on day 7, significant fall in MAP was seen in patients receiving labetalol. In the present study, the mean time required to control BP in group A was 42.22 hours and in group Bit was 36.97 hours. In group A, 40% patients required a dose of 750 mg/day to achieve optimal BPcontrol. Whereas 52% patients had their BP controlled with 300mg / day. Thus the rate of spontaneous labour was more in patients treated with labetalol. Patients in both group where in both group most common side-effect observed was headache. 8% patients in Group A and 7% patients in group B had this symptom. Conclusion: The freedom from maternal and fetal side-effects, the efficient hypotensive action indicates that labetalol is suitable for use during pregnancy.

Relation Between Labetalol and Methyldopa in Treatment of Pregnancy Induced Hypertension

Background: Hypertensive disorder is the most common medical problem encountered in pregnancy with a high perinatal and maternal mortality & morbidity. Worldwide about 76,000 pregnant women die each year from preeclampsia and related hypertensive disorders. Objective: To assess the relation between labetalol and methyldopa in treatment of pregnancy induced hypertension. Methods: This study was hospital based comparative prospective study was conducted at Dept. of Obstetrics & Gynaecology, Dhaka Medical College Hospital, Dhaka, Bangladesh from January to June 2021. The study consisted of 100 patients with pregnancy induced hypertension attending outpatient department and admitted in ANW, or who directly came to labour room. These patients were randomly selected on lottery basis after they fulfilled the inclusion criteria. Total patients were taken for the study and divided into 2 groups of 50 patients in each group. Results: A total 100 patients were included. The mean age in Group I was 24.4±4.55 years and in Group-II, 23.95±4.28 years. Maximum number of patients was between 19- 24 years in both the groups. In Group-I, 26 (52%) patients and in Group-II, 25 (50%) patients were in this age group. The maximum age in the Group I was 34 years and 35 years in the Group-II. The minimum age was 17 years in both the groups. The inter group difference was not statistically significant (p>0.05) thus the two groups were comparable by age. At baseline no significant difference was seen in SBP in both treatment groups. However after 8 days post testament SBP of women was significantly lower in Group-I patients as that of Group-II patients. i.e. Group-I: 123.41 vs. Group-II: 126.62, p- value=0.009. At baseline no significant difference was seen in DBP in both treatment groups. However at 8th day post treatment DBP of patients was significantly lower in Group-I patients. i.e. 77.18 vs. Group-II 79.64, p-value=0.005. For SBP more effective control was seen in women whose parity was 3-4 and for DBP notable difference was seen in women whose parity was 1-2. The control of systolic blood pressure was more effective in patients with normal body mass index and for Diastolic blood pressure (DBP) more effective control was seen in patients who were obese. On comparison methyldopa significantly causes more drowsiness, headache and nasal congestion and the incidence of Postural hypotension and dysponea in both groups were not significantly different. The patient who required additional drugs to control the uncontrolled hypertension. In Group I, 2 (4%) patients and in Group II, 3 (6%) patients did not respond with starting drug. The inter group difference was not statistically significant (p>0.05). Conclusion: Labetalol had less maternal adverse effect compared to methyldopa but fetal outcome was not observed in this study. Labetalol and methyldopa are equally efficacious in controlling blood pressure in new onset hypertension in pregnancy. This study is just a step in this long way. Therefore, labetalol can be considered positively in the treatment of pregnancy induced hypertension.

LABETALOL VERSUS METHYLDOPA IN TREATMENT OF HYPERTENSIVE DISORDERS OF PREGNANCY – A COMPARATIVE STUDY

Labetalol versus Methyldopa in treatment of hypertensive disorders of pregnancy – a comparative study - IJAR - Indian Journal of Applied Research(IJAR) IJAR is a double reviewed monthly print journal that accepts research works

To Compare the Efficacy of Labetalol and Methyldopa in Treatment of Pregnancy Induced Hypertension

To Compare the Efficacy of Labetalol and Methyldopa in Treatment of Pregnancy Induced Hypertension

Labetalol in Comparison to Methyl Dopa in Treatment of Gestational Hypertension, A Randomized Trial

Labetalol in Comparison to Methyl Dopa in Treatment of Gestational Hypertension, A Randomized Trial

Methyldopa in treatment of neurogenic bladder disorders

Fifty patients with neurogenic bladder dysfunction were treated with methyldopa (Aldomet). The preliminary results that are presented suggest a beneficial action in patients with upper neuron lesions. The probable mechanism of the drug's action is discussed.

Bethanidine, Guanethidine, and Methyldopa in Treatment of Hypertension: a Within-patient Comparison

Bethanidine, Guanethidine, and Methyldopa in Treatment of Hypertension: a Within-patient Comparison

Iodine balance in man

References BAYLIss, R.I.S. & HARVEY-SMITH, E.A. (1962) Methyldopa in the treatment of hypertension. Lancet, i, 763. CARSTAIRS, K.C., WORLLEDGE, S.M., DOLLERY, C.T. & BRECKENRIDGE, A. (1966) Methyldopa and haemolytic anaemia. Lancet, i, 201. DAWSON, A.A. & PALMER, K.N.V. (1966) A long-term follow-up of drug treatment in severe hypertension. Scot. med. J. 11, 113. DOLLERY, C.T. & HARINGTON, M. (1962) Methyldopa in hypertension: clinical and pharmacological studies. Lancet, i, 759. HAMILTON, M. (1966) Antihypertensive Therapy: Proceedings of an International Symposium, p. 196. Springer, Berlin. HAMILTON, M. (1966) The treatment of hypertension. Postgrad. med. J. 42, 195. HAMILTON, M., JENKINS, G.C. & TURNBULL, A.L. (1966) Methyldopa and haemolytic anaemia. Lancet, i, 549. HAMILTON, M. & KOPELMAN, H. (1963) Treatment of severe hypertension with methyldopa. Brit. med. J. i, 151. HANS, S.F. & KOPELMAN, H. (1964) Methyldopa in treatment of severe toxaemia of pregnancy. Brit. med. J. i, 736. IRVINE, R.O.H., O'BRIEN, K.P. & NORTH, J.D.K. (1962) Alpha methyldopa in treatment of hypertension. Lancet, i, 300. JOHNSON, P., KITCHIN, A.H., LOWTHER, C.P. & TURNER, R.W.D. (1966) Treatment of hypertension with methyldopa. Brit. med. J. i, 133. KINCAID-SMITH, P., BULLEN, M. & MILLS, J. (1966) Prolonged use of methyldopa in severe hypertension in pregnancy. Brit. med. J. i, 274. LoBUGLIO, A.S. & JANDL, J.H. (1967) Nature of the methyldopa red-cell antibody. New Engl. J. Med. 276, 658 SMIRK, SIR HORACE (1963) Hypotensive action ofmethyldopa. Brit. med. J. i, 148. VEILSGAARD, V., CHRISTENSEN, M. & CLAUSEN, E. (1967) Double-blind trial of four hypotensive drugs (Methyldopa and three sympatholytic agents). Brit. med. J. i, 598. WORLLEDGE, S.M., CARSTAIRS, K.C. & DACIE, J.V. (1966) Autoimmune haemolytic anaemia associated with amethyldopa therapy. Lancet, ii, 135.

Hans and Kopelman: Methyldopa in Treatment of Severe Toxemia of Pregnancy

Hans and Kopelman: Methyldopa in Treatment of Severe Toxemia of Pregnancy

METHYLDOPA IN TREATMENT OF SEVERE TOXAEMIA OF PREGNANCY.

METHYLDOPA IN TREATMENT OF SEVERE TOXAEMIA OF PREGNANCY.

Methyldopa in Treatment of Hypertension Due to Chronic Renal Disease

Methyldopa in Treatment of Hypertension Due to Chronic Renal Disease

Methydopa for treatment of hypertension.

Methyldopa is an enzyme inhibitor and an effective antihypertensive agent in man. In a study of 33 hypertensive patients, mean blood pressure levels were reduced more than 10% for the sitting position in 61%, and for the standing position in 71%. There were indications of liver damage in seven patients, probable drug fever in one, fluid retention in four, and aggravation of angina pectoris in two. The best indication for the use of methyldopa appeared to be renal insufficiency in hypertensive patients. The authors hesitate to advocate other than investigational use of this drug until the significance of its effects on the heart and liver are more clearly established.